Results 71 to 80 of about 70,663 (209)

Immunotherapy Deriving from CAR-T Cell Treatment in Autoimmune Diseases

Journal of Immunology Research, 2019
Chimeric antigen receptor T (CAR-T) cells are T cells engineered to express specific synthetic antigen receptors that can recognize antigens expressed by tumor cells, which after the binding of these antigens to the receptors are eliminated, and have ...
Yuehong Chen, Jianhong Sun, Huan Liu, Geng Yin, Qibing Xie   +4 more
doaj   +1 more source

Myeloid conditioning with c-kit-targeted CAR-T cells enables donor stem cell engraftment [PDF]

, 2018
We report a novel approach to bone marrow (BM) conditioning using c-kit-targeted chimeric antigen receptor T (c-kit CAR-T) cells in mice. Previous reports using anti-c-kit or anti-CD45 antibody linked to a toxin such as saporin have been promising.
Arai, Yasuyuki, Black, Mary A, Choi, Uimook, Corsino, Cristina I, Dinauer, Mary C, Feldman, Steven A, Koontz, Sherry M, Malech, Harry L, Sweeney, Colin L, Tajima, Masaki   +9 more
core   +2 more sources

The case for absolute ligand discrimination : modeling information processing and decision by immune T cells [PDF]

, 2015
Some cells have to take decision based on the quality of surroundings ligands, almost irrespective of their quantity, a problem we name "absolute discrimination". An example of absolute discrimination is recognition of not-self by immune T Cells. We show
Altan-Bonnet, Grégoire, François, Paul
core   +2 more sources

CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy

OncoImmunology, 2017
PD-L1/2 expression in solid tumors inhibits chimeric antigen receptor (CAR) T-cell efficacy. A PD-1 dominant negative receptor expressed in CAR T cells provides cell-intrinsic checkpoint blockade and augments antitumor efficacy.
Nan Chen, Aurore Morello, Zachary Tano, Prasad S. Adusumilli   +3 more
doaj   +1 more source

Targeting the tumor microenvironment in colorectal peritoneal metastases

, 2020
Peritoneal metastasis (PM) occurs in approximately one in four colorectal cancer (CRC) patients. The pathophysiology of colorectal PM remains poorly characterized. Also, the efficacy of current treatment modalities, including surgery and intraperitoneal (
Ceelen, Wim, De Wever, Olivier, Heriot, Alexander G., Narasimhan, Vignesh, Ramsay, Robert G.   +4 more
core   +1 more source

CAR-T cell. the long and winding road to solid tumors [PDF]

, 2018
Adoptive cell therapy of solid tumors with reprogrammed T cells can be considered the "next generation" of cancer hallmarks. CAR-T cells fail to be as effective as in liquid tumors for the inability to reach and survive in the microenvironment ...
A Heczey, AH Long, AM Leen, AP Cogdill, ARW Schröder, B Clémenceau, B Moldt, BD Koster, C Carpenito, C Zhang, CE Brown, CH June, CM Bollard, D Kobelt, DM Frey, DM Pardoll, DM Shayakhmetov, DW Lee, EI Buchbinder, EJ Lipson, EM Allen Van, F Bushman, F Ochi, F You, FS Hodi, G Gross, G Sconocchia, G Sconocchia, GL Beatty, H Karlsson, H Koehler, H Torikai, HC Ertl, HJ Pegram, I Caruana, J Badhiwala, J Ellis, J Wang, JE Bakema, JH Sampson, JL Tanyi, K Kono, K Kono, K Kudo, K Tamada, K Töpfer, KC Feng, L Bracci, L Zhang, LE Kandalaft, LM Rogers, LM Whilding, M Chmielewski, M Hegde, M Koneru, M Palma De, M Sadelain, M Sadelain, MA Ligtenberg, MC Milone, MCI Schalkwyk van, MD Stewart, ME Mikucki, ME Weijtens, MJ Besser, MJ Besser, MJ Butte, MJ Osborn, ML Davila, ML Davila, MM D’Aloia, MV Maus, N Ahmed, N Ahmed, O Walisko, P Kebriaei, PB Hackett, PC Schuberth, R Braster, R Monjezi, RA Morgan, RA Morgan, RJ Brentjens, RP Junghans, S Chabot, S Mohammed, S Nayak, S Sakaguchi, S Su, S Toyokuni, S Wilkie, SA Richman, SC Katz, SL Goff, SL Maude, SR Witting, SV Kulemzin, TR Medler, TR Simpson, V Arumugam, VD Fedorov, VD Sadelain, W Wang, XS Zhong, Z Eshhar, Z Grada, Z Wang   +106 more
core   +2 more sources

Production of Living Nanoparticles for Blood Cancer Therapy [PDF]

, 2018
Current cancer therapies leave much to be desired because they are very harmful to the patient and cause a significant decrease in quality of life. Chimeric Antigen Receptors (CAR) are a promising novel approach for treating specific types of leukemia ...
Mitchell, Peter, Pierotti, Michael, Piro, Matthew   +2 more
core   +1 more source

Irradiation to Improve the Response to Immunotherapeutic Agents in Glioblastomas. [PDF]

, 2019
PurposeGlioblastoma (GBM) remains an incurable disease despite extensive treatment with surgical resection, irradiation, and temozolomide. In line with many other forms of aggressive cancers, GBM is currently under consideration as a target for ...
Kaprealian, Tania, Lee, Mi-Heon, McBride, William H, Nesseler, Jean Philippe, Nickers, Philippe, Niclou, Simone P, Schaue, Dorthe   +6 more
core  

Chimeric antigen receptor T cell therapy for multiple myeloma

Inflammation and Regeneration, 2019
Chimeric antigen receptor (CAR) T cell therapy is a new cancer immunotherapy targeting cancer-specific cell surface antigen. CD19-CAR T cells have been already shown to be very effective to B cell leukemia/lymphoma.
Kana Hasegawa, Naoki Hosen
doaj   +1 more source

Development of novel adenoviral vectors to overcome challenges observed with HAdV-5 based constructs [PDF]

, 2011
Recombinant vectors based on human adenovirus serotype 5 (HAdV-5) have been extensively studied in pre-clinical models and clinical trials over the last two decades.
Julio Alonso-Padilla, Tibor Papp, Győző L Kaján, Mária Benkő, Menzo Havenga, Angelique Lemckert, Balázs Harrach, Andrew H Baker, Harrach, Benkő, Liu, Reddy, Benevento, Reddy, Rux, Bergelson, Wickham, Wolfrum, Arnberg, Burckhardt, Vectors used in gene therapy clinical trials., Appaiahgari, Pearson, Wilson, Chorny, Van Kampen, George, Ranki, Hendrickx, Ilan, Schaack, Aldhamen, Machitani, Appledorn, Perreau, Minamitani, Khare, Lyons, Carlisle, Seiradake, Xu, Khare, Qiu, Waddington, Kalyuzhniy, Vigant, Alba, Jonsson, Lenman, Doronin, Xu, Eichholz, Ganesan, Alemany, Piccolo, Mocanu, Piccolo, Khare, Xu, Lasaro, Zak, Zhang, Barouch, Bradley, Roberts, Gall, Fausther-Bovendo, Sumida, Miyazawa, Teigler, Smith, Molinier-Frenkel, Heemskerk, Hutnick, Tang, Olive, Leen, Joshi, Osada, Perreau, Seregin, Seregin, Fontanellas, Cerullo, Brunetti-Pierri, Seregin, Farrow, McConnell, Belousova, Seregin, Capasso, Green, Doronin, Kreppel, Matsui, Suzuki-Kouyama, Prill, Krasnykh, Zabner, Havenga, Lecollinet, Coughlan, Granio, Parker, Guse, Smith, Nicol, Bruder, Bruder, Baden, Coughlan, Mück-Häusl, Bi, Abbink, Abbink, Mastrangeli, Abrahamsen, Brough, Stone, Sirena, Stone, Seshidhar Reddy, Hemminki, Creech, Vogels, Kuhn, Di, Havenga, Kahl, Vogels, Lemckert, Teigler, Tameris, Ouédraogo, Keefer, Baden, Gilbert, Baden, Zahn, Johnson, Dakin, Alexander, Alexander, Gurwith, Lemiale, Jarecki-Khan, Saderi, Ko, Bangari, Ayalew, Hammond, Tuboly, Fischer, Hu, Greenall, Brake, Lopez-Gordo, Kremer, Soudais, Soudais, Silva, Puig, Fernandes, Tandon, Bangari, Nguyen, Lenaerts, Ying, van Olphen, Zakhartchouk, Cauthen, Reddy, Reddy, Li, Lenaerts, Sharma, Sharma, Roy, Cohen, Xiang, Quinn, Farina, Roy, Colloca, Barnes, O'Hara, Antrobus, Stanley, Tan, Michou, Ojkic, Sheppard, Corredor, Cherenova, Shashkova, Logunov, Both, Xu, Khatri, Hofmann, Löser, Both, Martiniello-Wilks, Tang, Fraser, Bridgeman, Doszpoly, Cortés-Hinojosa, Wigand, Kajon, Guy, Benkö, Lu, Günes, Wellehan, Phan   +215 more
core   +4 more sources